Dr Rishabh Jain· @DrRishabhOnco · X·· 12 小时前评分70
正文 · 机器翻译
🚨 一种个体化癌症疫苗刚刚取得了 III 期试验的成功！
🔥 INTerpath-001 | #ESMO26
在已切除的高危黑色素瘤中，intismeran + pembrolizumab 对比 pembrolizumab 单药：
📉 复发/死亡风险降低 42%（HR 0.58）
📊 24 个月 RFS：82.2% vs 70.0%
🎯 DMFS：HR 0.62（P=0.002）
⚠️ 注射相关 AE 更多，但大多数为低级别。
💡 个体化 mRNA 疫苗能否重新定义黑色素瘤辅助治疗？
@my_esmo @ESMO_open @ASCO @oncoalert
#Melanoma #CancerVaccine
165 浏览 · 2 赞 · 1 转发 · 0 回复
会议摘要
LBA1按 Presidential Symposium I 对上
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgINTerpath-001
https://esmocongress.esmo.org🚨 ESMO 2026: 15 Trials That Could Change Oncology Practice! From personalized cancer vaccines and bispecific antibodies to next-generation ADCs, major results are coming. 🔥 My Top 15 to Watch: 1. INTerpath-001 | Melanoma 2. SAFFRON | EGFR+ NSCLC 3. Krascendo 1 | KRAS G12C NSCLC 4. DeLLphi-305 | ES-SCLC 5. HARMONi-GI1 | Biliary 6. VOLGA | Bladder 7. DASL-HiCaP | Prostate 8. NATALEE | Breast 9. TRIO-US B-12 TALENT | Breast 10. ENERGIZE | Bladder 11. CLARITY-Gastric 01 | Gastric 12. KEYNOTE-C93 | Endometrial 13. KEYNOTE-B49 | Breast 14. LITESPARK-011 | RCC 15. SigVie-002 | NSCLC 📊 The big question: Which trials will deliver meaningful survival benefits and redefine standards of care? Not every positive trial is practice-changing. 👨⚕️ Oncologists, which trial are you watching most closely? #ESMO26 #Oncology #CancerResearch @ASCO @oncoalert @myesmo @esmo_open在 X 查看被引用的帖子
来源：Dr Rishabh Jain · x.com